AVROBIO, Inc. AVRO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

31/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

AVROBIO, Inc. (AVRO) generated $-14.46M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $27K, free cash flow was $-14.49M.

Cash conversion ratio was 0.41x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.41x suggests some earnings are non-cash items

Overall SharesGrow Score: 29/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

31/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

25/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

AVROBIO, Inc. Cash Flow History

Metric	TTM	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
Operating Cash Flow	$-60.08M	$-14.46M	$-17.82M	$-14.72M	$-13.08M
Capital Expenditure	$-208K	$-27K	$-154K	$-27K	$0.00
Free Cash Flow	$-60.29M	$-14.49M	$-17.97M	$-14.75M	$-13.08M